| Ethics and Nanopharmacy: Value Sensitive Design of New Drugs. | |
| | |
MedLine Citation:
|
PMID: 22247745 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Although applications are being developed and have reached the market, nanopharmacy to date is generally still conceived as an emerging technology. Its concept is ill-defined. Nanopharmacy can also be construed as a converging technology, which combines features of multiple technologies, ranging from nanotechnology to medicine and ICT. It is still debated whether its features give rise to new ethical issues or that issues associated with nanopharma are merely an extension of existing issues in the underlying fields. We argue here that, regardless of the alleged newness of the ethical issues involved, developments occasioned by technological advances affect the roles played by stakeholders in the field of nanopharmacy to such an extent that this calls for a different approach to responsible innovation in this field. Specific features associated with nanopharmacy itself and features introduced to the associated converging technologies- bring about a shift in the roles of stakeholders that call for a different approach to responsibility. We suggest that Value Sensitive Design is a suitable framework to involve stakeholders in addressing moral issues responsibly at an early stage of development of new nanopharmaceuticals. |
| | |
Authors:
|
Job Timmermans; Yinghuan Zhao; Jeroen van den Hoven |
Related Documents
:
|
704875 - Icru and icrp activities are important to radiologists and allied scientists. 11178375 - animal protection law in progress 22050135 - Ibs: transforming our governance. 11263135 - Ethical challenges in everyday practice for healthcare lawyers. 17411715 - Resolving the technologist shortage: a summary of acr and asrt efforts to meet the incr... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-9 |
Journal Detail:
|
Title: Nanoethics Volume: 5 ISSN: 1871-4765 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2012-1-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101311055 Medline TA: Nanoethics Country: - |
Other Details:
|
Languages: ENG Pagination: 269-283 Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells.
Next Document: Moral Arguments in the Debate over Nanotechnologies: Are We Talking Past Each Other?